Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
Rhea-AI Summary
Bausch Health Companies Inc. (NYSE/TSX: BHC) has scheduled the release of its fourth quarter and full year 2024 financial results for Wednesday, February 19, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST on the same day to discuss the results and provide a business update.
Interested parties can access all materials through the Investor Relations section of Bausch Health's website. A replay of the conference call will be made available on the investor relations website. To participate in the live Q&A session, participants must register in advance through the provided link.
Positive
- None.
Negative
- None.
News Market Reaction – BHC
On the day this news was published, BHC gained 1.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
Date: | Wednesday, February 19, 2025 |
Time: | 5:00 p.m. U.S. EST |
Webcast: |
A replay of the conference call will be available on the investor relations website.
To participate in the live Q&A session, please register using this link to receive an email confirming your registration.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
###
Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll-free)
Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 541-3785
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
When will Bausch Health (BHC) release Q4 and full year 2024 earnings?
What time is Bausch Health's (BHC) Q4 2024 earnings call?
How can I access Bausch Health's (BHC) Q4 2024 earnings materials?
How can investors participate in Bausch Health's (BHC) Q4 2024 earnings Q&A session?
